This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Russia claimed to have taken the villages of Hatyshche, Krasne, Morokhovets, and Oliinykove in Kharkiv Oblast. In Russia, the governor of Volgograd Oblast, Andrey Bocharov, claimed that a Ukrainian drone started a fire at an oil refinery, which was put out without any casualties. In Belgorod, officials claimed that 16 people were killed and 27 others were injured when a fragment of a Tochka-U struck an apartment building, according to the Russian Defence Ministry, which also claimed to have shot down several missiles over Belgorod Oblast. Ukrainian media later reported that the HUR carried out drone strikes in Volgograd, Lipetsk and Kaluga Oblasts. One person was killed by Russian shelling in Sumy Oblast. Officials reported that Ukraine's seaborne grain exports had recovered to close to their prewar level. The Kremlin announced the appointment of economist and Deputy Prime Minister Andrey Belousov as Defence Minister, replacing Sergei Shoigu who was transferred to become secretary of the Security Council of Russia.
==== Genomics ==== Genomics: Study of the genomes of organisms. Cognitive genomics: Study of the changes in cognitive processes associated with genetic profiles. Comparative genomics: Study of the relationship of genome structure and function across different biological species or strains. Functional genomics: Describes gene and protein functions and interactions (often uses transcriptomics). Metagenomics: Study of metagenomes, i.e., genetic material recovered directly from environmental samples. Neurogenomics: Study of genetic influences on the development and function of the nervous system. Pangenomics: Study of the entire collection of genes or genomes found within a given species. Personal genomics: Branch of genomics concerned with the sequencing and analysis of the genome of an individual. Once the genotypes are known, the individual's genotype can be compared with the published literature to determine likelihood of trait expression and disease risk. Helps in Personalized Medicine Electromics: Branch of genomics concerned with the role of exogenous electric fields in potentiating the gene expression profiles of cells, tissues, and organoids.
During continuous weekly intramuscular injections of CPA in men with prostate cancer, mean levels of CPA roughly doubled from 170 ng/mL (408 nmol/L) after the first injection to 310 ng/mL (744 nmol/L) after the fifth injection, and were projected to increase to 350 to 400 ng/mL (840–960 nmol/L) after around 8 to 12 injections. The area-under-the-curve (AUC; total exposure) levels of CPA with 100 mg/day oral CPA and 300 mg/week intramuscular CPA may be approximately equivalent.
== Medical career == Coatsworth is a Fellow of the Royal Australasian College of Physicians. His specialties are respiratory medicine and infectious diseases. He is currently director of infectious diseases at Canberra Hospital. His other roles have included executive director at the National Critical Care and Trauma Response Centre in Darwin. He has also lectured in medicine at the Australian National University. Coatsworth led humanitarian teams in the Congo and the Darfur region of Sudan for Medicins Sans Frontiers when he was 25, a task that he says left him with PTSD. He told the Today programme: "I think everyone has their limits in life and I kind of reached that, the security situation there was really difficult. There was the threat of assassination of people in the place where we were." After returning home, Coatsworth became anxious: "I felt like I was having these heart palpitations ... At the end of 2019 it got to the point one weekend I couldn't leave the house." He took anxiety medication to resolve the issue. He was elected to the board of Medicins Sans Frontiers in Australia in 2008. He served as the board's president in 2010 and 2011. He also led the second Australian Medical Assistance Team to the Philippines after Typhoon Haiyan in 2013. His other deployments with the Australian Medical Assistance Team include Vanuatu after Cyclone Pam in 2015 and Fiji following Cyclone Winston in 2016. In 2023, Coatsworth joined Patients Australia as Ambassador for Health Reform.
== I == Iatrogenic A condition unintentionally caused by medical treatment or diagnostic procedures. In neuroscience, may refer to nerve damage, seizures, or cognitive effects resulting from interventions. Ictal Relating to or occurring during a seizure or convulsion. Commonly used in the context of epilepsy, such as "ictal phase" versus "postictal phase." Imaging genetics A research field that combines brain imaging and genetics to investigate how genetic variation affects brain structure and function. Immunohistochemistry A technique that uses antibodies to detect specific proteins or antigens in tissue sections. Frequently used to visualize neuronal and glial markers. Implicit memory Unconscious memory of skills and procedures, such as riding a bike or playing an instrument. Associated with brain structures like the basal ganglia and cerebellum. Incus One of the three auditory ossicles in the middle ear that transmits sound vibrations from the malleus to the stapes. Independent component analysis (ICA) A computational method used to separate mixed signals into independent sources. Commonly used in EEG and fMRI to identify distinct brain activity patterns. Inferior colliculus A midbrain structure involved in auditory processing, particularly sound localization and reflexive responses to sound stimuli. Inferior olive A brainstem nucleus that sends climbing fiber inputs to the cerebellum and plays a critical role in motor learning and coordination.
Sources: en.wikipedia.org
==== Somatic and metabolic consequences ==== Like adults, OSA in children is linked to a higher risk for cardiovascular diseases, due to increased sympathetic activity and impaired cardiac autonomic control. Amongst the cardiovascular dysfunctions resulting from OSA, we can find systemic hypertension and blood pressure dysregulation (elevated blood pressure, or variability of the blood pressure for example). The variability of the blood pressure is correlated with the severity of the symptoms such as the frequency of the apnea and hypopnea. Pulmonary hypertension is also common amongst the cardiovascular problems resulting from OSA. Children with obstructive sleep-disordered breathing also show a faster heart rate during wakefulness and during sleep. In adult patients, OSA is associated with insulin resistance. In children, metabolic consequences of OSA are complicated to assess as they can also be associated to puberty and obesity (if present). However, when OSA is associated with obesity, the interaction of the two conditions can lead to metabolic disturbances such as insulin resistance and altered lipidemia, liver disease, abdominal adiposity and metabolic syndrome. Obesity interacts with those effects.
== Biodegradation and toxicity == Ciprofol is characterized by a rapid onset of action, and predictable absorption, distribution, metabolism, excretion processes. The compound undergoes glucuronidation in the liver, followed by excretion by the kidneys.
=== Approvals === Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. Viadur was approved by the FDA for palliative treatment of advanced prostate cancer on 6 March 2000. Eligard was approved by the FDA for palliative treatment of advanced prostate cancer on 24 January 2002. Fensolvi was approved by the FDA for children with central precocious puberty on 4 May 2020.
hydrophilic Soluble in or having an affinity for water or other polar compounds; describing a polar molecule, or a moiety or functional group within a molecule, which participates in intermolecular interactions such as hydrogen bonding with other polar molecules and therefore readily dissolves in polar solvents such as water or aqueous solutions. Unlike hydrophobic compounds, hydrophilic compounds can form energetically favorable contacts with the aqueous phase of biological fluids and so can often be suspended directly in the cytosol or exposed to extracellular spaces. Together, the contrasting properties of hydrophilicity and hydrophobicity play major roles in determining the structural conformations and functions of most biomolecules.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.